Transcept Pharmaceuticals Inc (NASDAQ:TSPT)

CAPS Rating: 2 out of 5

Results 1 - 7 of 7

Recs

0
Member Avatar SqwiiTrader (< 20) Submitted: 10/28/2013 9:02:02 AM : Outperform Start Price: $2.20 TSPT Score: -14.27

IHS

Recs

2
Member Avatar NHWeston (< 20) Submitted: 7/24/2012 12:35:59 PM : Underperform Start Price: $3.85 TSPT Score: +93.10

I'm not sure exactly what is wrong with this company. They have a number of good products but can't seem to make a market and are bleeding cash. Under other circumstances, you might see them as buy-out bait, but something just pushes the big boys away. Don't buy.

Recs

0
Member Avatar BuffettJunior1 (97.54) Submitted: 9/15/2011 2:37:18 PM : Underperform Start Price: $3.79 TSPT Score: +107.62

Terrible company!

Recs

0
Member Avatar chimpcontest (< 20) Submitted: 2/22/2011 11:07:40 AM : Outperform Start Price: $5.06 TSPT Score: -107.23

General Demon haiku (chimpcontest #1 winner, by the grace of God the stock went ratable this morning as it wasn't ratable on the weekend.)

Walking-dead groggies

Turn'em into pill-poppers

See profits galore

Recs

0
Member Avatar GeneralDemon (< 20) Submitted: 4/23/2010 1:12:40 PM : Outperform Start Price: $8.21 TSPT Score: -168.43

This is my first pitch regarding the subject of one stock in particular. I believe it may interest you if you have not heard of it yet.

This pitch will lack the usual good attempt at bad humor - so be forwarned.

The company is a small drug developer with a focus on producing the first FDA approved drug to treat the most common type of insomnia - MONI.

For the wikipedia description of MONI: http://en.wikipedia.org/wiki/Middle-of-the-Night_Insomnia

In short, people with MONI can fall asleep with no effort, but then wake up after a few hours and can never get back to sleep.

Do you ever wonder why people do crazy things - like swerve off the road and hit a tree, or worse, a kid, or fall asleep in somebody else's house (wait was that just being drunk)? Well, according to sleep experts, this stuff is costing many lives every year - thousands of deaths in the U.S. alone.

If you are not aware of how far people with severe, chronic insomnia will go for relief - just think of Michael Jackson. He was willing to risk death! I can relate because I suffer from this - and I have tried all of the current medications (Tylenol PM, Ambien and the like have no effect).

Regarding the stock:
The possible good:
Lots of cash for the approval process.
Huge potential market (millions of sufferers in the US alone)
The FDA's latest concern regarding safety (possible zombie driving accidents) is workable and can be managed (my personal opinion) - the solutions will be accepted by the insomniacs as a fair trade-off for the huge benefit. I envision lock boxes for car keys with a code that has to be entered (assuring the person is awake).

The possible bad:
The FDA may not ever approve the product. (No gurantee with any new drugs, of course)
Another company that I don't know about may be working on a superior product.
Additional adverse side effects may surface.
Company management could fumble.

zzlangerhans has greened thumbed the stock but has suggested people sell prior to final FDA decision. I probably will hold into the decision though (ha what a sucker, you say?)

Disclosure - Long TSPT

So what do you think? Did I put you to sleep?

Recs

0
Member Avatar gjuliantoro (< 20) Submitted: 10/5/2009 1:24:20 PM : Outperform Start Price: $8.72 TSPT Score: -168.18

Intermezzo will most definitely get FDA approval. Product has a large market share in the US ($250m est./yr) and in Europe (Estimated half of US sales)

Company has $6/share in equity and are planning to buy smaller bio companies to expand its revenue.

I am going long for this one. It should be in the 20's within 30 days.

Recs

0
Member Avatar speedom8 (< 20) Submitted: 9/4/2009 11:04:00 PM : Outperform Start Price: $7.87 TSPT Score: -167.84

promising research. No product out yet but about to get FDA approval and possibly get acquired by somebody.

Results 1 - 7 of 7

Featured Broker Partners


Advertisement